Clinical Trials Logo

Bacteremia clinical trials

View clinical trials related to Bacteremia.

Filter by:

NCT ID: NCT03643952 Completed - Bacteremia Clinical Trials

Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)

Start date: December 6, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to assess the safety, efficacy and pharmacokinetic (PK) parameters of daptomycin for injection in Japanese pediatric participants aged 1 to 17 years with complicated skin and soft tissue infection (cSSTI) or bacteremia caused by gram-positive cocci.

NCT ID: NCT03627884 Completed - Clinical trials for End Stage Renal Disease

Outcomes of the Use of Sodium Bicarbonate (8.4%) Solution as a Catheter Lock Solution to Prevent Hemodialysis Catheter Loss Due to Lumen Clot Formation

Start date: October 1, 2016
Phase: Phase 4
Study type: Interventional

Prospective, randomized, comparative clinical and open-label trial comparing sodium bicarbonate catheter lock solution (SBCLS) to normal saline catheter lock solution (NSCLS) use in HD patients with central venous catheters (CVC).

NCT ID: NCT03611257 Completed - Clinical trials for Hematologic Diseases

Effect of dRAST on Treatment for Bacteremia in Patients With Hematologic Diseases

Start date: September 1, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to evaluate whether the use of direct rapid antibiotic susceptibility test (dRAST), in addition to the current standard antibiotic susceptibility test, can increase the proportion of patients with hematologic disease who received appropriate antibiotics in early period of bacteremia.

NCT ID: NCT03597841 Completed - Bacteremia Clinical Trials

Turkish Prospective Cohort Study on Carbapenem Resistant Klebsiella Pneumonia Bacteremia

THREAT
Start date: June 25, 2018
Phase:
Study type: Observational

Carbapenem-resistant Klebsiella pneumonia (CRKp) blood stream infections (BSI) cause substantial mortality among hospitalized patients. Treatment options for CRKp infections are limited and increasing resistance rates to few available drugs, i.e., colistin, is a big concern. This prospective multicenter observational study is designed to describe clinical characteristics and outcomes of patients with CRKp bacteremia in an oxacillinase-48 (OXA-48) endemic country to define predictors of mortality with a focus on the impact of mono versus combination therapies on mortality. The study will also investigate risk factors associated with colistin-resistant CRKp BSI.

NCT ID: NCT03577366 Completed - Bacteremia Sepsis Clinical Trials

Prevalence and Characterization of Diagnostic Error Among Patients With Bacteremia

Start date: January 1, 2016
Phase:
Study type: Observational

Diagnostic error is an important but often under-recognized source of adverse events in the hospital. This study is focused on the delayed or missed diagnosis of sepsis associated with bacteremia among patients admitted to The Ottawa Hospital. The aim of this study is to determine the prevalence and characterization of diagnostic error among patients admitted to the at The Ottawa Hospital with sepsis associated with a positive blood culture. This study will consist of a retrospective chart review of all patients who are greater than 18 years with positive blood culture taken within 12 hours of presenting to the Emergency Department of Ottawa Hospital Civic and General Campus between January 2016 to August 13th 2017. For charts that are eligible for review for diagnostic errors, the qSOFA (Quick Sequential [Sepsis-related] Organ Failure Assessment) score at time at admission will be used to identify those patients who were at risk of serious harm because of a missed diagnosis of sepsis and lack of treatment. Patient variables will be collected and compared between the following three groups: (1) patients who received antibiotics within 24 hours, (2) patients who did not receive antibiotics within 24 hours and who did not meet qSOFA criteria, and (3) patients who did not receive antibiotic within 24 hours and who met qSOFA criteria. Variables to be studied include age, gender, hospital campus, admitting service, day of admission (weekend vs. weekday), time of admission (night vs. day), length of stay, disposition and Elixhauser Comorbidity Index. For charts eligible for review for diagnostic error, the DEER (Diagnostic Error Evaluation Research) Taxonomy tool will be used to classify cases per the location and type of error that occurred in the diagnostic process.

NCT ID: NCT03497741 Completed - Sepsis Clinical Trials

Predictive Value of Procalcitonin for Bacteremia in the ICU

Start date: October 1, 2017
Phase:
Study type: Observational

Association between plasma procalcitonin levels and positive blood cultures in critical illness patients in the ICU.

NCT ID: NCT03441126 Completed - Sepsis Clinical Trials

Blood Culture Improvement Guidelines and Diagnostic Stewardship for Antibiotic Reduction in Critically Ill Children

Bright STAR
Start date: April 1, 2018
Phase:
Study type: Observational

This study will test the hypothesis that reliable implementation of an evidence-based clinical practice guideline for evaluation of patients with signs and symptoms of sepsis will decrease antibiotic use in pediatric intensive care units (PICUs).

NCT ID: NCT03356249 Completed - Sepsis Clinical Trials

Next-Generation Sequencing Diagnostics of Bacteremia in Sepsis

NextGeneSiS
Start date: March 1, 2019
Phase:
Study type: Observational

Sepsis remains a major challenge, even in modern intensive care medicine. The identification of the causative pathogen is crucial for an early optimization of the antimicrobial treatment regime in patients with sepsis. In this context, culture-based diagnostic procedures (e.g. blood cultures) represent the standard of care, although they are associated with relevant limitations. Therefore, culture independent methods (e.g. Next-Generation Sequencing (NGS)) seem to be an attractive alternative. By the identification of circulating cell-free DNA in the blood and the use of the quantitative sepsis indicating quantifier (SIQ) score, causing pathogens can be identified and potential contaminations can be excluded. The goal of the presented study is therefore, to assess the diagnostic performance of a NGS-based approach for the detection of relevant infecting organisms in a big cohort of septic patients (n=500). Moreover, the plausibility of this NGS-based approach will be estimated by a panel of independent clinical specialists, retrospectively identifying potential changes in patients´ management based on NGS results.

NCT ID: NCT03309137 Completed - Infection Clinical Trials

Device for Bacteremia Prevention in Post Cardiac Surgical Intensive Care Unit Patients

CHG-Lockā„¢
Start date: November 19, 2017
Phase: N/A
Study type: Interventional

Intravenous catheters are often placed in large (central) veins in critically ill patients to provide special medications or frequent blood sampling. The body reacts to the presence of foreign material by forming a biofilm on the surface within the catheter. Either due to the patients condition or to emergency access to these intravenous lines can become infected with bacteria and reside within the biofilm. When bacteria is grown from these lines it is referred to as: a central line infection. A medical device company (ICU Medical) has obtained the rights to a device that delivers a controlled amount of a cleaning material called chlorhexidine into the catheter to prevent bacterial growth when not in use. Chlorhexidine is the standard cleaning material used on patients when cleaning the skin for surgical procedures or central intravenous catheter insertion. In laboratory tests and animal studies that chlorhexidine inhibits the growth of bacteria and fungi that often cause central line infections. This study will the first assessment in patients with central lines.

NCT ID: NCT03248973 Completed - Clinical trials for Listeria Monocytogenes

Successful Treatment of Maternal Listeria Monocytogenes Bacteremia in the First Trimester

Start date: April 3, 2017
Phase:
Study type: Observational

Successful Treatment of Maternal Listeria Monocytogenes Bacteremia in the First Trimester of Pregnancy